🔬Help Us Better Support Scientists Worldwide!💜 🔗Take our Global Survey: medchemexpress.com/global-ma… 🌎Join the MedChemExpress Research Community by sharing your information. Stay connected with us to access the latest research resources and discover how MCE’s products and services can support your scientific journey. Thank you for being part of the scientific community driving innovation forward. 🧪 #LifeScience #ScientificResearch #Biotechnology #DrugDiscovery #ResearchCommunity

🧬How has the drug target landscape evolved over the past 25 years? A new review in Nature Reviews Drug Discovery takes a closer look at the drug targets behind medicines approved by the FDA, EMA, and PMDA since 2000. As of June 2025, the analysis identified: 🔹 686 biomolecular targets modulated by 🔹 1,702 approved drugs 🔬 25 years of drug discovery have reshaped the druggable space: • Endogenous #peptide targets increased 7.2-fold • Small molecules and biologics reached similar numbers of new approvals in 2023 • 136 #kinase inhibitors have been developed against 67 kinase targets • Emerging modalities are opening new opportunities beyond traditional drug discovery approaches 💡The druggable space is not fixed. As technologies and therapeutic modalities evolve, so does our ability to translate new biology into medicines. From emerging targets to new modalities, MCE supports your drug discovery journey. medchemexpress.com/ #DrugDiscovery #DrugTargets #DrugDevelopment #Pharma #Biopharma #Pharmacology

👶Research Spotlight | How do mothers shape the infant #microbiome? A new review in @TrendsMicrobiol examines how, when, and through which routes microbes are shared between mothers and infants. 🔹Maternal microbes can reach infants through multiple routes 🔹Timing may influence which microbes establish and persist 🔹Early microbial exposure can shape infant microbiome development 🧬Understanding these transmission pathways offers new insights into how the infant microbiome develops during early life. 🔗Read more: cell.com/trends/microbiology… #InfantMicrobiome #Microbiology #MaternalHealth #InfantHealth #GutMicrobiome #MicrobialEcology

🧠Research Spotlight | Could disrupted lipid homeostasis be an overlooked driver of Alzheimer’s disease? A new Molecular Neurodegeneration review highlights how human cellular models are reshaping our understanding of lipid biology in Alzheimer’s disease: 🧬AD genetic risk → lipid dysregulation 🧫iPSC-derived neurons, astrocytes & microglia reveal cell-specific vulnerabilities 🔄Lipid transfer between neurons and glia may contribute to non-cell-autonomous dysfunction 🔬Lipidomics, imaging, isotope tracing & multi-omics enable deeper mechanistic analysis This review highlights lipid homeostasis as an important area for understanding AD mechanisms and identifying potential targets beyond amyloid-β. 🔗Read more: link.springer.com/article/10… 🧪Explore AD-related research tools from MedChemExpress: medchemexpress.com/disease-a… #AlzheimersDisease #Neuroscience #Lipidomics #APOE4 #iPSC #Neurodegeneration #MolecularNeurodegeneration

🚨#FDA Approval Update | Lirafugratinib Approved for FGFR2+ #Cholangiocarcinoma The FDA has approved Lyrfigtu (#Lirafugratinib) for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring #FGFR2 gene fusions or other rearrangements. 🔬 In the REFOCUS trial: • ORR: 46% • Median DOR: 11.8 months 🎯A new targeted treatment option for FGFR2-altered cholangiocarcinoma. #Oncology #DrugDevelopment

🚨#FDA Approval Update | First approved treatment for #ataxia in ataxia-telangiectasia The FDA has approved #Aqneursa (#levacetylleucine) oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing ≥15 kg. 🧬A-T is a rare inherited neurodegenerative disorder caused by mutations in the ATM gene, with progressive loss of muscle control and coordination. 📊In a randomized, double-blind, placebo-controlled crossover study of 73 patients, Aqneursa improved neurological function as measured by the functional Scale for the Assessment and Rating of Ataxia (fSARA). 🔗Read more: fda.gov/drugs/news-events-hu… 🧪Explore levacetylleucine for research use from MedChemExpress: medchemexpress.com/n-acetyl-… #FDAApproval#AtaxiaTelangiectasia #RareDisease #GeneticDisease #Neurology #DrugDevelopment

🧬Research Spotlight | Could the gut #microbiome in early childhood help predict type 1 diabetes risk? A new @NatMetabolism study analyzed 12151 longitudinal metagenomes from 887 children in the TEDDY study, revealing three distinct patterns of gut microbiome maturation: 🔹Early Matured 🔹Late Matured 🔹Early Plateaued Notably, the Early Plateaued pattern was associated with a 3-fold higher risk of type 1 diabetes, while host genetic variants linked to antimicrobial and antiviral immune responses modified the association between microbiome maturation and T1D risk. The findings highlight how early-life microbiome development and host genetics may interact in #T1D susceptibility. 🔗Read more: nature.com/articles/s42255-0… 🧪Explore T1D-related research tools from MedChemExpress: medchemexpress.com/disease-a… #Type1Diabetes #GutMicrobiome #Genetics #Immunology #NatureMetabolism

🚨#FDA Approval Update | A new combination for Breast Cancer with #ESR1 mutations The FDA approved #imlunestrant (#Inluriyo) + #abemaciclib (#Verzenio) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on ≥1 line of endocrine therapy. In the phase 3 EMBER-3 trial, among patients with ESR1-mutated tumors: 🔹Median PFS: 11.1 vs 5.5 months 🔹HR for progression/death: 0.53 🔹ORR: 35% vs 15% 🔬Explore MedChemExpress's tools for #BreastCancer research: medchemexpress.com/disease-a… #ER #ESR1 #HER2 #FDAApproval

🧬 Research Spotlight | How has the drug target landscape evolved over the past 25 years? A new review in @NatRevDrugDisc maps the changing landscape of drug targets and modalities: 🔹686 biomolecules modulated by 1,702 drugs as of June 2025 🔹312 new MoA targets introduced since 2000 — an 84% increase 🔹7.2× increase in endogenous peptide targets 🔹Biologics have reshaped the target landscape, expanding access to extracellular and cell-surface proteins The review highlights how advances in genomics, structural biology, screening technologies, and new drug modalities are expanding the range of targets accessible to drug discovery. 🔗Read more: nature.com/articles/s41573-0… 🔎Explore Drug Target Identification Services from MedChemExpress: medchemexpress.com/us/en/dru… #DrugDiscovery #DrugTargets #MedicinalChemistry #Pharma #Biologics

🎯Science Visuals | #TNBC in 2026: From “Target-Limited” to More Targeted Strategies Triple-negative breast cancer (#TNBC) lacks three common therapeutic targets—ER, PR, and HER2 and has historically been challenging to treat. But the treatment landscape is changing. In 2026, the FDA expanded TNBC treatment options with two #TROP2 -directed #ADCs: 🔹Datroway (#datopotamab #deruxtecan) — approved for unresectable or metastatic TNBC. 🔹Trodelvy (#sacituzumab #govitecan) — approved for first-line treatment of TNBC, including in combination with #pembrolizumab for PD-L1–positive TNBC. Beyond these approvals, TNBC research is increasingly focusing on: 🧬#ADC + #Immunotherapy combinations 🔬Biomarker-driven treatment, including TROP2, PD-L1, BRCA1/2, and HRD 🧪#PARP inhibitors and DNA damage response strategies 🎯New approaches for early-stage TNBC with residual disease What new vulnerabilities can we target? MedChemExpress supports breast cancer research with the tools and resources to help drive the next breakthrough. medchemexpress.com/disease-a… #BreastCancer #BRCA #CancerResearch #PrecisionMedicine #DrugDiscovery

🧬Research Spotlight | What controls the execution of #ferroptosis? A new @Nature study identifies mitochondrial fission factor (MFF) as a key regulator linking organelle dynamics to ferroptotic cell death. 🔹17-HETE → MFF Ser155 phosphorylation 🔹Mitochondrial & peroxisomal fragmentation → oxidative stress 🔹PKCβ-MFF-DUSP22 axis regulates MFF phosphorylation 🔹MFF-SPARK enables real-time monitoring of ferroptosis 🔹Avermectin B1 activates the PKCβ-MFF axis and sensitizes tumors to ferroptosis in vivo These findings reveal MFF phosphorylation as a central node connecting organelle remodeling and ferroptosis and provide new tools for studying this regulated cell death pathway. 🔗Read more: nature.com/articles/s41586-0… 🧪Explore ferroptosis-related research tools from MedChemExpress: medchemexpress.com/Targets/F… #Ferroptosis #MFF #CellDeath #CancerResearch #OxidativeStress

🔬Research Spotlight | #EGFR-mutant #NSCLC The phase 2 AMIGO-1 trial met its primary endpoint with first-line amivantamab + lazertinib + pemetrexed: 🔹66.7% 18-month PFS 🔹25.1-month median PFS 🔹85% objective response rate The triplet showed promising efficacy, while safety and treatment-related toxicity remain important considerations. 🔎Explore the study: onclive.com/view/amigo-1-tri… MedChemExpress offers amivantamab for research use only: medchemexpress.com/amivantam… #LungCancer #CancerResearch #amivantamab #lazertinib #pemetrexed

🎨Science Visuals | #HIV (Human Immunodeficiency Virus): From Infection to Immune System Damage HIV targets CD4+ T cells, gradually weakening the immune system. Without effective treatment, advanced HIV infection can progress to AIDS. Antiretroviral therapy (ART) can suppress HIV, help preserve immune function, and reduce the risk of sexual transmission. 🌏Fiji has reported a sharp increase in new HIV infections and declared a national HIV crisis in response. 🔬Understanding how HIV spreads and affects the immune system is essential for prevention, testing, and continued research. MedChemExpress offers HIV-related research tools: medchemexpress.com/disease-a… #HIV #AIDS #HIVResearch #PublicHealth #Immunology #HIVInfection

🏆Citation Laureates 2026 | What scientific breakthroughs could shape the future? 89 Citation Laureates have gone on to receive #NobelPrizes since 2002. In the newly announced 2026 Citation Laureates, groundbreaking research spans GLP-1 medicines, precision gene editing, optical imaging, and immunology. Among the recognized breakthroughs: 💊GLP-1 research Daniel Drucker, Jens Juul Holst, and Svetlana Mojsov were recognized for their pioneering work on GLP-1 and its biological activity—foundational discoveries that helped pave the way for today’s GLP-1-based therapies. 🧬Precision gene editing David R. Liu was recognized for developing base editing and prime editing, technologies that enable precise DNA modification and open new possibilities for programmable medicines. 🔬Optical medical imaging James G. Fujimoto and colleagues were recognized for the development of optical coherence tomography (#OCT), advancing biomedical imaging. 🧪 Immune cell adhesion Timothy A. Springer was recognized for discoveries revealing key adhesion receptors in the immune system. From fundamental discoveries to transformative technologies, these breakthroughs show how high-impact research can advance our understanding of biology, disease, and new therapies. clarivate.com/citation-laure… #CitationLaureates2026 #GLP1 #GeneEditing #BaseEditing #PrimeEditing #Immunology #DrugDiscovery #BiomedicalResearch #ScientificDiscovery

🧠Research Spotlight | What do ion channels have to do with hemiplegic #migraine? A new JCI review highlights how mutations in CACNA1A, ATP1A2, and #SCN1A can alter neuronal excitability and increase susceptibility to cortical spreading depression (CSD), a key mechanism underlying migraine aura. 🔬Altered Ca²⁺ signaling, disrupted ion homeostasis, and impaired glutamate clearance can all contribute to neuronal hyperexcitability and increased CSD susceptibility. Read more: jci.org/articles/view/208001 🧪Explore migraine-related research tools from MedChemExpress: medchemexpress.com/disease-a… #Migraine #Neurology #Neuroscience #Genetics

🧬Research Spotlight | Does biological #aging look different in females and males? A new Nature Medicine study developed 38 sex-specific biological aging clocks across 15 organ systems and 3 omic layers. The clocks revealed sex-dependent differences in: 🔹Genetic architecture of aging 🔹Organ-specific molecular signatures 🔹Disease and mortality associations 🔹Brain aging and cognitive decline in Alzheimer’s disease 📊The study suggests that biological aging is highly sex- and organ-specific, and that sex-stratified aging clocks can uncover genetic, molecular, and clinical signals that conventional sex-pooled models may obscure. 🔗nature.com/articles/s41591-0… MedChemExpress offers tools for anti-aging research: medchemexpress.com/NaturalPr… #BiologicalAging #AgingResearch #Omics #Alzheimers

🚨#FDA Approval Update | A new approach to addressing muscle loss in #SMA The #FDA has approved #Isembyld (#apitegromab-mstn) for adults and children ≥2 years with spinal muscular atrophy (#SMA) who are receiving an SMN2-targeted treatment. As the first FDA-approved SMA therapy to directly target muscle loss, Isembyld is designed to complement existing approaches that target the underlying motor neuron loss. 📊In a Phase 3 trial, Isembyld 10 mg/kg showed improved motor function at 1 year, with 34.2% of patients achieving a clinically meaningful improvement vs. 13.5% with placebo. 🔬MedChemExpress offers apitegromab for research use only: medchemexpress.com/apitegrom… #SpinalMuscularAtrophy #RareDisease #NeuromuscularDisease #Biotech #DrugDevelopment #MedChemExpress

🔬Research Spotlight | Can chronic interferon signaling actually help tumors grow? A new study in Science uncovers a surprising mechanism linking chronic type II interferon signaling to tumor growth and immunotherapy resistance: IFN-II → mitochondrial RNA release → IFN-I signaling → COX-2/PGE₂ → immunosuppression In an immunotherapy-resistant melanoma model, targeting PGE₂ synthesis restored responsiveness to anti-PD-1 treatment. 🧬These findings reveal a potential link between mitochondrial RNA, interferon signaling, and the tumor microenvironment. 🧪Explore Prostaglandin E2 for research use from MedChemExpress: medchemexpress.com/Prostagla… Read more: science.org/doi/10.1126/scie… #CancerResearch #Immunology #Interferon #Immunotherapy #Melanoma